将替诺喹重新定位为抗耳念珠菌复合体严格 senso stricto 的强效抗真菌剂
本研究通过体外试验评估抗疟药替诺喹对严格 senso stricto 的耳念珠菌复合体的抗真菌活性,MIC 为 4 mg/L,显著抑制生物膜形成 60.63%,并 impair 线粒体功能;在 Tenebrio molitor 幼虫模型中无溶血或急性毒性,治疗 3 天后生存率约 60%。结论认为替诺喹是有前景的抗真菌药物重定位候选。
要点
- 替诺喹对严格 senso stricto 的耳念珠菌复合体 MIC 为 4 mg/L,具杀真菌活性。
- 替诺喹显著抑制生物膜形成 60.63%,并 impair 线粒体功能导致细胞呼吸受损。
- Tenebrio molitor 幼虫模型中无溶血或急性毒性,治疗 3 天生存率约 60%。
核心结论
- 替诺喹有望作为抗真菌药物重定位的候选,尤其针对严格 senso stricto 的耳念珠菌复合体。
研究设计与样本
- 体外试验检测替诺喹对严格 senso stricto 的耳念珠菌复合体的 MIC、最低杀真菌浓度、生物膜抑制、细胞损伤、细胞膜完整性、核苷酸泄漏、山梨醇保护试验和外排泵抑制。
- 通过溶血试验评估细胞毒性,并使用 Tenebrio molitor 幼虫进行体内安全性和有效性测试。
主要发现
- 替诺喹对严格 senso stricto 的耳念珠菌复合体 MIC 为 4 mg/L,并显著抑制生物膜形成 60.63%。
- 替诺喹损害线粒体功能,导致细胞呼吸受损;未引起显著蛋白泄漏,表明其机制不同于膜靶向药物。
- 在 Tenebrio molitor 模型中未观察到溶血或急性毒性;替诺喹抗真菌治疗 3 天后生存率约 60%。
关键数值与推荐
- 替诺喹对严格 senso stricto 的耳念珠菌复合体的 MIC 为 4 mg/L。
- 替诺喹显著抑制生物膜形成 60.63%。
- 替诺喹治疗 3 天后 Tenebrio molitor 幼虫生存率约 60%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The rise in fungal infections caused by multidrug-resistant pathogens like Candida haemulonii sensu stricto presents a significant global health challenge. The common resistance to current treatments underscores the urgency to explore alternative therapeutic strategies, including drug repurposing. OBJECTIVES: To assess the potential of repurposing tafenoquine, an antimalarial agent, for antifungal use against C. haemulonii sensu stricto. METHODS: The efficacy of tafenoquine was tested using in vitro assays for minimum inhibitory concentration (MIC), minimum fungicidal concentration, biofilm inhibition, cell damage, cell membrane integrity, nucleotide leakage, sorbitol protection assay, and efflux pump inhibition. The compound's cytotoxicity was assessed through a haemolysis assay, and in vivo safety and efficacy were tested using Tenebrio molitor larvae. RESULTS: Tafenoquine exhibited potent fungicidal activity against C. haemulonii sensu stricto with an MIC of 4 mg/L and significantly inhibited biofilm formation by 60.63%. Tafenoquine also impaired mitochondrial functionality, leading to compromised cellular respiration. Despite these effects, tafenoquine did not cause significant protein leakage, indicating a distinct mechanism from membrane-targeting agents. In vivo study confirmed tafenoquine's non-toxic profile with no observed haemolysis or acute toxicity in the T. molitor model. During antifungal treatment with tafenoquine, a survival rate of approximately 60% was observed after 3 days. CONCLUSIONS: The findings of this study highlight tafenoquine's potential as a promising candidate for antifungal drug repurposing, especially against C. haemulonii sensu stricto. Its effectiveness in inhibiting fungal growth and biofilm formation underscores its viability for further clinical development as a novel antifungal therapy.
引用
- Pimentel LR, Lucini F, Silva GAD, et al. Repurposing tafenoquine as a potent antifungal agent against Candida haemulonii sensu stricto. J Antimicrob Chemother. 2025. PMID: 39992314. doi:10.1093/jac/dkaf054
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。